Move to topTop

TOKYO, JAPAN - November 26, 2020 - Terumo Corporation (TSE: 4543) today announced that it will construct additional production facilities for pre-filled syringes at the headquarter plant of Terumo Yamaguchi D&D Corporation, a Terumo subsidiary.The capital investment for the project will total JPY 15 billion including some expense for adjacent facilities. Construction is to begin in August 2021, and the main facility is expected to start operation in December 2023. This investment will increase the production capacity at Terumo Yamaguchi D&D by 3.5 times as compared to 2016, when the factory first commenced.

Terumo Yamaguchi D&D Corporation manufactures drug-device combination products such as Hulio® (adalimumab biosimilar)*1 for the treatment of diseases such as rheumatoid arthritis, and Teribone™ 28.2 µg subcutaneous autoinjector*2 for osteoporosis.

The Alliance Division of Terumo's General Hospital Company is engaged in the contract development and manufacturing organization (CDMO) business, leveraged by the company's advanced manufacturing technology for drug-device combination products. The division also provides drug administration devices to pharmaceutical companies, which are all designed from materials tailored to each drug. Both business models utilizes the experience and expertise Terumo has built up through its years.The annual revenue ended March 2020 of the Alliance Division was JPY 23.6 billion, with a 16% growth year-on-year. The division expects further growth and it is anticipated it will be the driving force for General Hospital Company's earnings.

  • *1

    Hulio® is a product of FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.

  • *2

    Teribone™ is a product of Asahi Kasei Pharma Corporation

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Media Contact

Corporate Communication Dept., Terumo Corporation

Contact us

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.

News TOP